New hope for toughest blood cancers: scientists tweak transplant drugs to fight disease and spare patients
NCT ID NCT07238712
Summary
This study aims to improve outcomes for patients with high-risk blood cancers who receive a stem cell transplant from a partially matched donor. Researchers are testing a modified combination of two drugs (bendamustine and cyclophosphamide) given after the transplant. The goal is to maintain the cancer-fighting power of the transplant while reducing the risk of severe, life-threatening immune reactions and other complications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pavlov University
RECRUITINGSaint Petersburg, 197022, Russia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.